Human growth hormone treatment and Creutzfeldt-Jakob disease

1986 ◽  
Vol 9 (5) ◽  
pp. 439-439 ◽  
Author(s):  
A. Sartorio ◽  
M. Arosio ◽  
G. Faglia ◽  
M. Resentini ◽  
F. Morabito
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Growth Hormone Treatment ◽  
Human Growth ◽  
Hormone Treatment ◽  
Jakob Disease

Recombinant human growth hormone treatment in children with thalassemia major

1999 ◽  
Vol 41 (6) ◽  
pp. 655-661 ◽  
Author(s):  
AYTEN Arcasoy ◽  
GÖNÜL Öcal ◽  
SABRI Kemahli ◽  
MERIH Berberoİlu ◽  
YILDIZ Yildirmak ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Growth Hormone Treatment ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Hormone Treatment ◽  
Thalassemia Major

scholarly journals Effect of One-Year Growth Hormone Therapy on Cardiometabolic Risk Factors in Boys with Obesity

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Jing Wu ◽  
Fei Zhao ◽  
Yuan Zhang ◽  
Jiang Xue ◽  
Jiangying Kuang ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Hormone Therapy ◽  
Human Growth Hormone ◽  
Growth Hormone Treatment ◽  
Growth Hormone Therapy ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Hormone Treatment ◽  
Risk Markers ◽  
One Year

It has been recognized that people with obesity are more likely to have low growth hormone secretion. Recent studies have also confirmed that the abnormalities of the growth hormone/insulin-like growth factor 1 axis were associated with cardiovascular complications in people with obesity. However, little is known about whether recombinant human growth hormone therapy could improve cardiovascular and metabolic risks in obese children. This study aims to evaluate the effect of one-year growth hormone therapy on obesity-related comorbidities and to assess the safety in Chinese boys with obesity. Eighteen boys with obesity were treated with recombinant human growth hormone for one year. Anthropometric measurements, endocrine testing, and cardiovascular risk markers were performed in all obese boys in baseline, and follow-up visits were performed at 3 months, 6 months, 9 months, and one year, respectively. After one year of recombinant human growth hormone treatment, the body mass index standard deviation scores decreased (P<0.001) and insulin-like growth factor 1 levels increased (P<0.001). GH treatment also reduced low density lipoprotein cholesterol (P<0.001), total cholesterol (P<0.001), triglycerides (P=0.042), and alanine aminotransferase (P=0.027) when compared with the baseline. One-year of recombinant human growth hormone treatment could improve cardiometabolic risk markers, without adverse effects on glucose homeostasis in boys with obesity.

Human growth hormone treatment in prepubertal children with achondroplasia

1996 ◽  
Vol 61 (4) ◽  
pp. 396-400 ◽  
Author(s):  
Giovanna Weber ◽  
Chiara Prinster ◽  
Marta Meneghel ◽  
Fiorella Russo ◽  
Stefano Mora ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Growth Hormone Treatment ◽  
Human Growth ◽  
Hormone Treatment ◽  
Prepubertal Children

Recombinant human growth hormone treatment of children with chronic renal failure: long-term (1- to 3-year) outcome

1991 ◽  
Vol 5 (4) ◽  
pp. 477-481 ◽  
Author(s):  
Richard N. Fine ◽  
Kim Pyke-Grimm ◽  
Pauline A. Nelson ◽  
M. Ines Boechat ◽  
Barbara M. Lippe ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Renal Failure ◽  
Chronic Renal Failure ◽  
Human Growth Hormone ◽  
Growth Hormone Treatment ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Hormone Treatment
Sign in / Sign up

Export Citation Format

Share Document